Peptide therapy is a powerful tool for enhancing overall health and addressing specific medical conditions
While one study did show statistical significance, the FDA said in a Complete Response Letter that it was insufficient on its own [to provide] substantial evidence of effectiveness. The FDA also noted that the NDA submission lacked data on concomitant antipsychotic administration, did not include data that established that the change in negative symptoms was clinically meaningful and that the submitted safety database had an inadequate number of subjects exposed to roluperidone at the proposed dose of 64 mg for at least 12 months
It also improves endothelial function by lowering ET-1 and thromboxane B2 levels while increasing CGRP levels, inhibits apoptosis by modulating B-Cell Lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), and caspase-3 expression, and suppresses NOD-like receptor protein 3 (NLRP3) inflammasome activation via the toll-like receptor 4 (TLR4)/NF-B signaling pathway (Guo et al., 2015)
Much of the trial literature is industry-funded, sample sizes are modest, and the field lacks standardization across collagen types, molecular weights, and hydrolysis profiles
